Blog > Editor's Pic > Gift-of-life technology could spell big bucks for Cerus Corp. (CERS)
Share this article:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • NewsVine
  • StumbleUpon
  • Twitter

Gift-of-life technology could spell big bucks for Cerus Corp. (CERS)

Today's Financial News - Posted September 1, 2009

TFN’s Laura Cadden believes that today’s steep sell-off in Cerus Corporation (NASDAQ:CERS) provides an excellent buying opportunity!

by J. Christoph Amberger

Baltimore, MD — TFN: Biotech and small pharma stocks have made a big splash over the past couple of days. We’ve seen — and in some cases taken! — substantial gains in our open positions, bot in our TFN recommendations and our premium service HSC picks.

Don’t tell Laura, but I’m passing on one of her “between-issues” recommendations to Hot Stock Confidential readers to you. You’ll see why…

This is what she sent out today:

“You saw the jump (89% in just one day!) Cerus Corporation (NASDAQ:CERS) made on its INTERCEPT system’s approval by the Swiss for the extended storage of blood platlets. Many of you banked gains anywhere from 53% to 72%. [We recorded a 54% gain for the HSC portfolio on August 19.]

“I remain bullish on this company. Now that the price has again dropped, I think we should get back in. It’s all about the company. Here’s why:

“Unlike whole blood donations, which can be stored for up to 42 days, platelets are typically held for just 5 days. Cerus can treat those platelets to allow that storage time to be extended to 7 days. This is what the Swiss have embraced.

“As a regular platelet donor, I’m in a unique position to know how crucial this is. Within 7 days of my last donation, a charming lady named Debbie with a strong Baltimore accent calls me to schedule my next. Sometimes she even provides specifics, ‘We have 3 liver transplants scheduled and there are 2 shooting victims at area hospitals. We really need your help.’

“A neonatologist friend tells me that sometimes, it’s difficult to locate even a thimble-full of platetlets for her tiny patients.

“Then there’s the constant need from cancer patients going through chemotherapy.

“The ability to store platelets safely for a longer period would have a significant impact. But it isn’t just platelets. The company’s technology is designed to destroy pathogens in all donated blood components. Many of their systems are in place in different countries in Europe. I’m confident Cerus will get approval from the FDA when they’ve completed their ongoing Phase III trials.

“Let’s get back in so when can enjoy those gains when they do! I recommend you buy shares of Cerus Corporation (NASDAQ:CERS) under $2.”

Again. You didn’t hear it from me.


Next Article: TFN eNews 09/01/2009: Musings of a reluctant optimist… and a great recommendation!

Related Articles

Posted by J. Christoph Amberger · Filed Under Editor's Pic 

Share this article:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • NewsVine
  • StumbleUpon
  • Twitter

 Add to Technorati Favorites | Follow Us on Twitter!

Be the first to leave a reply.

Your comments are welcome